Post-effective amendment to a registration statement that is not immediately effective upon filing

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) AND MEZZANINE EQUITY

v3.22.2.2
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) AND MEZZANINE EQUITY - P3 Health Partners Inc. - USD ($)
Additional Paid-in Capital
Accumulated Deficit
Common Stock
Common Class A
Common Stock
Common Class V
Redeemable Non-Controlling Interests
Total
Financial Designation, Predecessor and Successor [Fixed List]           Predecessor
Financial Designation, Predecessor and Successor [Fixed List]           Successor
STOCKHOLDERS' EQUITY (DEFICIT) at Dec. 31, 2021 $ 312,945,752 [1] $ (39,418,124) $ 4,158 $ 19,655   $ 273,551,441
STOCKHOLDERS' EQUITY (DEFICIT) (in shares) at Dec. 31, 2021     41,578,890 196,553,523    
Balance at the end at Dec. 31, 2021         $ 1,790,617,285  
STOCKHOLDERS' EQUITY (DEFICIT) at Dec. 03, 2021 312,945,752 [1] (29,336,924) $ 4,158 $ 19,655   283,632,641
STOCKHOLDERS' EQUITY (DEFICIT) (in shares) at Dec. 03, 2021     41,578,890 196,553,523    
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Loss   (10,081,200)       (10,081,200)
STOCKHOLDERS' EQUITY (DEFICIT) at Dec. 31, 2021 312,945,752 [1] (39,418,124) $ 4,158 $ 19,655   273,551,441
STOCKHOLDERS' EQUITY (DEFICIT) (in shares) at Dec. 31, 2021     41,578,890 196,553,523    
Balance at the beginning at Dec. 03, 2021         1,833,838,872  
Increase (Decrease) in Temporary Equity [Roll Forward]            
Stock Compensation         4,635,142  
Net Loss         (47,856,729)  
Balance at the end at Dec. 31, 2021         1,790,617,285  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Loss   (10,577,504)       (10,577,504)
STOCKHOLDERS' EQUITY (DEFICIT) at Mar. 31, 2022 312,945,752 (49,995,628) $ 4,158 $ 19,710   $ 262,973,992
STOCKHOLDERS' EQUITY (DEFICIT) (in shares) at Mar. 31, 2022     41,578,890 197,103,345    
Increase (Decrease) in Temporary Equity [Roll Forward]            
Stock Compensation         11,711,427  
Net Loss         (50,212,750)  
Financial Designation, Predecessor and Successor [Fixed List]           Successor
STOCKHOLDERS' EQUITY (DEFICIT) at Dec. 31, 2021 312,945,752 [1] (39,418,124) $ 4,158 $ 19,655   $ 273,551,441
STOCKHOLDERS' EQUITY (DEFICIT) (in shares) at Dec. 31, 2021     41,578,890 196,553,523    
STOCKHOLDERS' EQUITY (DEFICIT) at Jun. 30, 2022 312,945,752 (204,345,577) $ 4,158 $ 20,142   $ 108,624,475
STOCKHOLDERS' EQUITY (DEFICIT) (in shares) at Jun. 30, 2022     41,578,890 201,423,309    
Balance at the beginning at Dec. 31, 2021         1,790,617,285  
Financial Designation, Predecessor and Successor [Fixed List]           Successor
STOCKHOLDERS' EQUITY (DEFICIT) at Mar. 31, 2022 312,945,752 (49,995,628) $ 4,158 $ 19,710   $ 262,973,992
STOCKHOLDERS' EQUITY (DEFICIT) (in shares) at Mar. 31, 2022     41,578,890 197,103,345    
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net Loss   (154,349,949)       (154,349,949)
STOCKHOLDERS' EQUITY (DEFICIT) at Jun. 30, 2022 $ 312,945,752 $ (204,345,577) $ 4,158 $ 20,142   $ 108,624,475
STOCKHOLDERS' EQUITY (DEFICIT) (in shares) at Jun. 30, 2022     41,578,890 201,423,309    
Increase (Decrease) in Temporary Equity [Roll Forward]            
Stock Compensation         3,715,553  
Net Loss         $ (748,755,990)  
[1] Included in the opening balance are transactions completed in connection with the Business Combinations, including the PIPE investment of $195.3 million (net of issuance costs), the equity consideration to P3 shareholders of $80.3 million, and the trust proceeds (net of redemptions) of $37.4 million.